Antibody-Drug Conjugate Era in Gynaecological Cancers
New antibody-drug conjugates (ADCs) are transforming treatment for advanced ovarian and endometrial cancers, with the European Medicines Agency (EMA) approving two landmark drugs this week—mirvetuximab soravtansine and trastuzumab deruxtecan—marking the ... Read More